Onconova Implementation Guide
0.2.0 - ci-build

Onconova Implementation Guide - Local Development build (v0.2.0) built by the FHIR (HL7® FHIR® Standard) Build Tools. See the Directory of published versions

Extensions

Extensions The following extensions have been defined for this implementation guide:

  • Adverse Event CTCAE Grade

    The grade of the adverse event as defined by the Common Terminology Criteria for Adverse Events (CTCAE).

  • Adverse Event Mitigation

    Details about an action taken to mitigate or manage the adverse event.

  • Adverse Event Resolved Date

    The date when the adverse event was resolved (if applicable).

  • Cancer Patient Age at Diagnosis

    The approximate age of the patient at the time of diagnosis of the disease.

  • Cancer Patient Age

    The approximate age of the patient.

  • Cancer Patient Cause of Death

    The cause of death for the patient.

  • Cancer Patient Clinical Center

    The center or hospital where the patient case original records were recorded.

  • Cancer Patient Consent status

    The status of whether the patient has given or revoked consent for research use.

  • Cancer Patient Data Completion Rate

    The percentage of data elements categories that have been completed for a patient.

  • Cancer Patient Data Contributors

    The individuals or organizations that contributed to the patient's case data collection.

  • Cancer Patient End of Records

    Indicates the last known record date of a patient.

  • Cancer Patient Overall Survival

    The duration of time from either the date of diagnosis or the start of treatment for a disease, such as cancer, that patients diagnosed with the disease are still alive. In a clinical trial, measuring the overall survival is one way to see how well a new treatment works.

  • Cancer Patient Vital status

    The status of whether the patient is alive or deceased or unknown.

  • Cancer Stage Breslow Depth

    The actual measured Breslow depth as a quantity

  • Family Member History Cancer Morphology

    The morphology of a historical cancer associated to a family member of a patient, represented by an ICD-O-3 code.

  • Family Member History Cancer Topography

    The topography of a historical cancer associated to a family member of a patient, represented by an ICD-O-3 code.

  • Family Member History Condition Contributed to Death

    Whether the condition contributed to the patient's family member's death

  • Genomic Variant Assessment Date

    Date at which the genomic variant was assessed and/or reported.

  • Histological Differentiation

    The histological differentiation of the tumor.

  • Homologous Recombination Deficiency Interpretation

    The categorical classification of the HRD status interpreted from its value.

  • Medication Administration Adjunctive Role

    Indicates the role of this medication administration in the context of the overall treatment plan.

  • Medication Administration Combined With

    Indicates which medication administrations were given in combination with the current medication administration.

  • Medication Administration Cycles

    Indicates the total number of cycles for this medication administration.

  • Medication Administration Is Primary Therapy

    Indicates whether this medication administration is the primary therapy within a therapy line.

  • Molecular Tumor Board CUP Characterization

    A characterization of the tumor board review focused on cancer of unknown primary (CUP) origin.

  • Molecular Tumor Board Molecular Comparison

    A comparison of molecular findings discussed during the molecular tumor board review.

  • Molecular Tumor Board Therapeutic Recommendation

    A therapeutic recommendation or follow-up action resulting from a molecular tumor board review.

  • Primary Cancer Recurrence Of

    Indicates that the condition is a recurrence of a previous condition, and provides a reference to that previous condition.

  • Primary Cancer Recurrence Type

    Indicates the type of recurrence for the condition (local or regional).

  • Risk Assessment Score

    The numerical score of the risk assessment.

  • Therapy Line Intent

    The intent of the therapy line, such as curative or palliative.

  • Therapy Line Number

    The number representing the sequence of the therapy line in the overall treatment regimen.

  • Therapy Line Progression Date

    The date when disease progression was observed during or after the therapy line.

  • Therapy Line Progression-Free Survival

    The progression-free survival duration for the therapy line.

  • Therapy Line Reference

    A reference to the therapy line associated with this treatment.

  • Treatment Response RECIST Is Interpreted

    Indicates that whether the RECIST was interpreted from a radiology report rather than extracted.

  • Tumor Board Specialization

    The specialization or focus area of the tumor board conducting the review, such as hematologic malignancies or solid tumors.

  • Tumor Marker Analyte

    The specific analyte or substance being measured as a tumor marker, such as PSA, CA-125, or CEA.

  • Tumor Mutational Burden Status

    The categorical classification of the TMB status interpreted from its value.